Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on understanding the best treatment approaches of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Todd Bauer as the primary speaker and Dr. Ullas Batra as a moderator who will share the important facts associated with treatment approaches for management of ALK positive lung cancer.
Dr. Todd Bauer has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, a discussion on all possible treatment approaches and their pros, cons are discussed.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Testosterone recovery linked to overall survival in high-risk prostate cancer
2.
Knowing about and avoiding bladder cancer.
3.
AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence
4.
How 7,000 steps a day could help reduce your risk of cancer
5.
ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?
1.
Cancer Stem Cells: The Seeds of Tumorigenesis and Recurrence
2.
Clinical Analysis of Prostate Cancer
3.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
4.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
5.
Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation